

1 Autoimmunity and Antibody Dependent COVID-19 Enhancement of SARS CoV-2
2 Vaccination: A Global Human Right to Know then Decide.

3 Mina T. Kelleni, MD, PhD

4 Pharmacology Department, College of Medicine, Minia University, Egypt

5 mina.kelleni@mu.edu.eg; drthabetpharm@yahoo.com

6 Mobile: +201200382422

7 <https://orcid.org/0000-0001-6290-6025>

8 Highlights

9 Some SARS CoV-2 vaccines have been investigated and all have not been fully approved.
10 SARS CoV-2 vaccines might induce autoimmunity that could be fatal.
11 SARS CoV-2 induced antibody dependent enhancement has not been excluded yet.
12 An informed personalized risk benefit ratio must be secured.


13 Abstract

14 SARS CoV-2 vaccines are being advertised as a tool to beat COVID-19, yet with the
15 emergence of different variants that are suggested to be vaccine-resistant, and the
16 emergence of SARS CoV-2 vaccine induced serious adverse effects a personalized risk
17 benefit ratio should be carefully assessed. mRNA based and adenovirus vectored vaccines,
18 types of nucleic acid-based vaccination, were first ever or first commercially ever approved
19 for the public, respectively. However, these new types possess a potential risk to induce
20 auto-immune diseases e.g., thrombocytopenia and some of these complications might also
21 reason for some of the post vaccination sudden death reports e.g., autoimmune myocarditis
22 and immune induced thrombosis and thromboembolism. Moreover, all SARS CoV-2 types
23 of vaccines, depending on the spike protein immunogenicity, especially the conventional
24 inactivated ones might increase the likelihood of COVID-19 severity upon re-infection
25 through antibody dependent enhancement which might also reason for some of the serious
26 adverse effects encountered with administration of convalescent plasma to COVID-19
27 patients. Moreover, these vaccines might have shared in development of the potentially

more lethal SARS CoV-2 B.1.617 variants and might lead to evolution of more virulent ones. Finally, A moral, legal, and sacred constitutional public right to know and decide basing on a personalized risk benefit ratio must be secured. Finally, it is a real misfortune that a draft of this manuscript is being denied an opportunity to be properly peer reviewed by numerous reputable medical journals for more than six months and even before a single mortality was reported and we totally condemn, from a medical point of view, any national or international policy that necessitates these experimental vaccines and we also condemn the trials in children as well as the European Court of Human Rights shameful ruling that compulsory vaccination would not contravene human rights law and we suggest that the rapid race to develop and approve SARS CoV-2 vaccines might eventually end with a man-made Hades.

Keywords: COVID-19, SARS CoV-2, Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccine, Johnson & Johnson Ad26.COV2-S vaccine, Pfizer-BioNTech BNT162b2 vaccine, Moderna mRNA-1273 vaccine, autoimmune diseases, antibody dependent enhancement.

Graphical abstract



Introduction

Safe COVID-19 vaccines are considered of utmost importance to stem SARS CoV-2 current pandemic [1]. However, the unprecedented accelerated timelines to develop some of COVID-19 vaccines have necessitated a critical call for active pre- and post-licensure safety surveillance systems to properly investigate potential adverse effects or toxicities [1-3]. Importantly, whether the incidence of SARS CoV-2 vaccine related serious adverse effects might be considered rare or less rare [https://www.smh.com.au/national/astrazeneca-advice-unlikely-to-change-despite-rate-of-rare-clotting-doubling-20210427-p57mq8.html] and very difficult to be prove causation[4], the scientific community has an obligation to continue developing new standards for safety monitoring and most importantly the public has a moral and legal right to know the potential hazards of COVID-19 newly approved vaccines in order to freely decide whether or not to receive any after an informed personalized risk benefit ratio is provided.

Interestingly, autoimmunity developing due to similarities between viral and human proteins is one of the known sequelae of viral infections that include short term and sometimes permanent damage to the CNS[5]. However, this risk associated with COVID-19 vaccines especially the newly approved SARS CoV-2 ones is yet to be discovered. In this manuscript, we briefly discuss the potential autoimmune adverse effects of SARS CoV-2 nucleic acid-based vaccines; adenovirus vectored and mRNA vaccines. Furthermore, we also briefly discuss the potential risk to develop more severe COVID-19 upon SARS CoV-2 reinfection after vaccination as compared to the natural infection; a phenomenon called antibody dependent disease enhancement and its potential association with adverse effects encountered while convalescent plasma was administered to COVID-19 patients. Finally, we illustrate, from our point of view, some of the higher risk groups to develop autoimmune disorders wishing they might consider a personalized risk benefit ratio, and measures that might decrease this potential. We wish to confirm that the public has a moral, legal, and constitutional right to know all the potential risks including the rarest ones to allow an informed personalized risk benefit ratio to be weighed and decided. This right should never be argued or suppressed as, unfortunately, it appeared as the case

when a professional peer review for this and other related preprinted manuscripts has been previously denied by several well reputed medical journals.

Adenovirus vectored vaccines potential autoimmunity risk

Autoimmunity developing due to similarities between viral and human proteins is one of the known sequelae of viral infections that include short term and sometimes permanent damage to the CNS[5]. Moreover, an increased autoimmunity risk was hypothesized due to the inclusion of new adjuvants into the already approved licensed vaccines[6]. However, this risk associated with COVID-19 vaccines especially the newly approved SARS CoV-2 ones is yet to be discovered.

Notably, adenovirus vectored SARS CoV-2 vaccine has been first commercially approved to be used in humans in Russia which is currently undergoing a mass vaccination program. Moreover, on December 30, 2020, it has also been announced to be authorized for emergency supply in the UK followed by other countries.

Importantly, two adenovirus vectored SARS CoV-2 vaccine global phase III clinical trials were temporarily paused due to reports of serious adverse medical events of autoimmune and/or inflammatory complications including multiple sclerosis and transverse myelitis which were ultimately deemed to be unrelated to the SARS CoV-2 vaccine. Moreover, lack of transparency concerns have been raised as the involved companies declined the release of the thorough details of these serious adverse events claiming patients' privacy issues [7-10] and a sharp criticism of the analysis of the results of one trial including a serious dose mistake, claimed later to be a beneficial mistake, that involved thousands of patients has also been raised[11]. Importantly, supraphysiological expression levels of spike proteins in some individuals who receive nucleic acid based vaccination might share in development of autoimmune reactions [12] and we suggest that a skewed immune virus spike protein-antibody complex might trigger and reason, at least partly, for this potential autoimmunity [13] and we recommend that the dose of the nucleic acid based vaccines, if decided to be received, should be optimized to the lowest possible and preferably to be given once and potential tools to prevent such reactions should be further developed and tested.

mRNA vaccines potential autoimmunity risk

mRNA based vaccines, first approved in UK for COVID-19 as a first ever approval for this novel type of vaccination in a western country to be followed by USA, the European Medicines Agency as well as several countries worldwide, possess multiple theoretical and manufacturing advantages over traditional subunit, live attenuated and killed virus vaccines[14-16]. However, their remarkable high efficacy in SARS CoV-2 clinical trials contradicted the results of other previous clinical trials using mRNA vaccines to prevent H10N8, H7N9 influenza and rabies viruses which have been lower than what was expected when compared to those of their preclinical studies[15]. Moreover, though mRNA vaccines encoding HIV and CMV antigens elicited antigen-specific CD4+ and CD8+ T cell immune responses; no reduction in viral load was observed[14].

Importantly, potential risks of mRNA, and saRNA, based vaccines include risk of autoimmunity due to development of autoreactive antibodies of any non-native nucleotides and delivery system components. Furthermore, the identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination was advised [15,17,18]. Notably, other than the currently known potential risks of anaphylaxis or Bell's palsy (<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>), soon after mRNA based SARS CoV-2 vaccine approval, the Norwegian Medicines Agency is investigating the potential causation of Pfizer-BioNTech mRNA (BNT162b2) vaccine against Covid-19 and the death of 75-year-old and elder 33 recipients. Similarly, the Paul Ehrlich Institute in Germany has been reported to investigate 10 fatalities that occurred within four days of vaccination and whose age groups were not revealed to the public but described as previously seriously ill patients suffering from many underlying diseases[19]. Alarming, though attributing these fatalities to commonly encountered adverse effects in the elderly is usually advocated, yet an otherwise healthy 56-year-old American obstetrician and gynecologist has developed autoimmune thrombocytopenia three days after receiving BNT162b2 vaccine and later he was deceased of brain hemorrhage as a complication to this autoimmune disease. Similarly, another American 60-year-old X-ray technologist was deceased four days after taking his second dose of the BNT162b2 vaccine, he complained of an acute abdominal pain and dyspnea and tested

negative for COVID-19, later his condition deteriorated, was put into a medically induced coma and a ventilator and finally he suffered from severe hypotension before death. Other than overweight and hypertension, he has not complained of any concomitant disorder. Moreover, at least one participant in the clinical trials has suffered from cardiac arrest (<https://www.reuters.com/article/uk-factcheck-pfizer-health-concerns-idUSKBN28K2R6>) and an otherwise healthy 41-year-old Portuguese nurse was found dead two days after receiving BNT162b2 vaccine. Similarly, a frightening analysis has seriously doubted the integrity of the safety data reported by the Israeli ministry of health as regards to it adopted policy for mass vaccination with BNT162b2 vaccine [http://www.nakim.org/israel-forums/viewtopic.php?t=270812&s=The_uncovering_of_the_vaccination_data_in_Israel_reveals_a_frightening_picture&fbclid=IwAR3qTWwbnGVhmkhjOqDktSaYB_QAGTBkk1SETlrxS0GJvDOMMXl5W8qPjuA] and an informal weak criticism of this report has confirmed the validity of its statistics [<https://www.lesoleil.com/actualite/verification-faite/verification-faite-un-vaccin-qui-aggrave-les-symptomes-vraiment-653bb8c18253322defd076a115d8a83e>]. Additionally, another report claims that there is a post BNT162b2 mass vaccination increasing Israeli all-cause mortality with an observational “murky wave of heart attacks” as well as suggestions of intended official lack of transparency [https://swprs.org/israel-why-is-all-cause-mortality-increasing/?fbclid=IwAR0WX4OUR67KWZrxpVqBmV5Z_Xhl114cJv4wCqJo2BzF_Fd7kbnWXg6LHo4]. Interestingly, though the official statements denies a single post SARS CoV-2 vaccination mortality [<https://www.reuters.com/article/uk-factcheck-israel-idUSKBN2AA2TS>], unofficial reports strongly contradict this claim [<https://www.facebook.com/lindsayfoord/videos/10157458591032391>] and one might ask for independent international investigations for the best interests of transparency.

Adenovirus vectored and mRNA vaccines common autoimmune risks.

Importantly, immune thrombocytopenia was previously attributed to IgG opsonized dengue virus complexes bound to Fc receptors in platelets which were also suggested to play a central role in development of antibody dependent enhancement during dengue infection[20] and we suggest that the same mechanism might also apply to reason for the reported post BNT162b2 and Moderna mRNA-1273 SARS CoV-2 mRNA vaccination

induced thrombocytopenia [<https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-covid-vaccine-blood.html>] that also led the EMA to start a review of safety signal in patients who received any of BNT162b2, mRNA-1273 and Oxford/AstraZeneca (ChAdOx1 nCoV-19) (adenovirus vectored) vaccines [<https://www.reuters.com/article/brief-ema-reviews-safety-signal-of-immun-idUSFWN2LA0PH>]. Moreover, autoantibody induced thrombosis was previously described in another setting[21] as well as other potential mechanisms for immunothrombosis[22] and venous thromboembolism was shown to be consistently associated with autoimmune diseases[23] and we suggest that a dysregulated autoimmunity might be triggered in some individuals who received SARS CoV-2 vaccines leading to sudden death from thromboembolism though only ChAdOx1 nCoV-19 vaccine has been in focus because of multiple simultaneous fatality reports that led some European countries to halt its administration, at least temporarily, as becoming usual, while falsely claiming similar incidence in the general population [<https://www.dw.com/en/covid-several-european-countries-halt-use-of-astrazeneca-vaccine/a-56835406>] as the abstract facts refute this claim and declare that these vaccine related extremely serious adverse effects are more frequent than would be expected by chance [https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et cid=3703486]. Importantly, the reported cerebral venous sinus thrombosis, encountered post ChAdOx1 nCoV-19 vaccination [<https://www1.racgp.org.au/newsgp/clinical/atagi-review-of-astrazeneca-covid-vaccines-what-gp>] was previously described with autoimmune thyroiditis/hypothyroidism [24] and its risk factors include the presence of autoantibodies like antiphospholipid and anticardiolipin antibodies[25] and fortunately some scientists from Norway and Germany have independently confirmed the ability of ChAdOx1 nCoV-19 to trigger this autoimmune reaction [<https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w>] and later AstraZeneca was instructed to flag a possible thrombotic side-effect of ChAdOx1 nCoV-19 vaccine on labelling

[<https://www.reuters.com/article/us-health-coronavirus-astrazeneca-statem/astrazeneca-to-flag-possible-blood-clot-side-effect-of-covid-19-vaccine-on-labelling-idUSKBN2BU2Z5>]. Recently, vaccine-induced immune thrombotic thrombocytopenia was coined to describe the pathogenesis of these cases[26].

Ironically, the same sequence of denial, investigations appears to occur with the Johnson & Johnson adenovirus vectored SARS CoV-2 Ad26.COV2-S vaccine and the FDA initially declared that currently no causal thrombosis relationship is found [<https://www.reuters.com/article/us-health-coronavirus-europe-vaccines/jj-covid-19-vaccine-under-eu-review-over-blood-clots-idUSKBN2BW2FI>], but fortunately a prompt vigilant decision of a temporary pause of Ad26.COV2-S vaccine until further evaluation was issued [<https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine>]. Notably, we have formally contacted the FDA before this pause and emailed a draft of this manuscript and later we urged it to respond like EMA and wisely they did [<https://edition.cnn.com/2021/04/23/health/johnson-vaccine-acip-recommendation/index.html>]. Most recently some European countries have fully suspended the use of ChAdOx1 nCOV-19 vaccine and even UK has restricted its use to people over 40 years old instead of those over 30 years old [<https://www.reuters.com/world/uk/uk-advises-under-40s-take-alternative-astrazeneca-covid-19-shot-2021-05-07/>] and analysis of its association with the autoimmune Guillain-Barré syndrome [<https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/>].

Unsurprisingly, British scientists have retaliated and recently exposed that post SARS CoV-2 vaccines thrombotic events are not limited to the cerebral vasculature as splanchnic and portal vein thrombosis with similar case fatality rate (18.8% versus 20% of cerebral venous thrombosis) within two weeks post vaccination are more common with BNT162b2 and mRNA-1273 vaccines (44.9 per million versus 1.6 per million for their ChAdOx1 nCOV-19 vaccine) and they have mentioned that the incidence is much higher after COVID-19 but we suggest that their comparison is not out of bias especially when properly adjusted for the affected age and gender [27,28] and one may wonder what else is hidden

and when it will be exposed. Moreover, we would like to suggest that a fatal autoimmune myocarditis, which is known to be underdiagnosed, might also be responsible for some of the post SARS CoV-2 mRNA vaccination sudden death reports which are being attributed to other adverse effects which are not directly related to mRNA vaccine while they might be due to vaccine related myocarditis causing due to fatal arrhythmias, acute-onset heart failure with cardiogenic shock, pericardial effusion with cardiac tamponade [29,30]. Importantly, a 19-year-old Israeli patient suffered from tachycardia, dyspnea, and angina like pain after receiving his second dose of BNT162b2 vaccine to be hospitalized five days later with a confirmed diagnosis of myocarditis. Importantly, since IL-6 has been suggested to play an integral role in the pathogenesis of clinical and experimental viral myocarditis[31,32], we would like to suggest that the potential clinical benefits of few days administration of NSAIDs with SARS CoV-2 vaccines[33] either concomitantly or on the day after both the first and second (if there is one) jabs might eventually exceed the inconclusive potential risk to lower the immune response developed from the vaccines[34]. Recently and fortunately, EMA has begun an investigation to assess the association between SARS CoV-2 mRNA vaccines and myocarditis has started with the usual declaration that no indication at present that these cases were due to the vaccines [<https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/>].

Notably, supraphysiological expression levels of spike proteins in some individuals who receive nucleic acid based vaccination might share in development of autoimmune reactions and we suggest the dose of the nucleic acid based vaccines should be optimized to the lowest possible dose and potential tools to prevent such reactions should be further developed and tested [12]. Moreover, an immunopathological phenomenon called antibody dependent enhancement that might cause COVID-19 enhancement, discussed later, should be tested for a potential concomitant correlation. Some vaccines recipients who were previously primed by either SARS CoV-2 as silent infection or possibly through other commonly encountered corona viruses, might express an autoimmune lung reaction which was suggested to reason for COVID-19 pathogenesis[5,35] and we suggest it might better suit COVID-19 complications whether or not linked to vaccination.

BNT162b2 vaccine potential extra risk

Importantly and unfortunately, the sequence used in BNT162b2 vaccine was suggested to induce misleading errors in translational decoding and protein synthesis that were hypothesized to produce serious long-term health damage including neurodegenerative diseases and multiple sclerosis[36]. Furthermore, several adjuvants newly used in vaccines are known to trigger the innate and adaptive immune system with a theoretical, not confirmed, risk to induce autoimmune diseases[6] and since most of the serious adverse effects and fatalities are reported with the BNT162b2 vaccine, there is a likelihood for at least a short-term potential hazard that might be a company specific, to be also fully investigated and compared as regards to sequence and used adjuvants it to its mRNA-1273 counterpart as an essential component of any investigation. Furthermore, we would like to recommend CDC to urgently change its neutral recommendation and to advice against administration of nucleic acid-based vaccines to persons complaining from autoimmune diseases [<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>]. Finally, we recommend consideration of an immediate reevaluation of the emergency approval granted by the FDA to BNT162b2 vaccine until full investigations of the claims against its design and its potential causation of some of the reported deaths are performed and discussed.

Antibody dependent COVID-19 enhancement potential risk: vaccines and convalescent plasma links

Importantly, an unexplored risk for all types of SARS CoV-2 vaccines, especially the inactivated ones, that aim to develop antibodies against its spike protein is an immunopathological well recognized phenomenon called antibody dependent enhancement which was reported and described with other respiratory and corona viruses including SARS CoV and MERS [5,37]. It was previously reported that in the presence of vaccine-elicited antiviral antibodies, SARS-CoV displayed an altered tropism toward primary human immune cells which were otherwise refractory to the virus. Furthermore, vaccines developed against animal coronaviruses has demonstrated an immune enhancement of disease in vaccinated recipients[38]. Importantly, individuals suffering from severe COVID-19 were suggested to be primed by one or more prior coronavirus

exposures, and due to antigenic epitope heterogeneity, are experiencing the effects of ADE similar to that previously postulated with SARS CoV[39]. Additionally, recurrent COVID-19 infection was described, in a significant minority due to a variable immune response, to be more severe and potentially fatal[40]. Interestingly, SARS CoV-2 vaccines were also suggested to possess the same risk and a modification of their design was suggested to lower the potential risk[5]. Notably, a higher antibody titres against SARS-CoV-2 being associated with more severe disease and suggested to be linked to ADE as one possible probability that was not excluded by the other suggested mechanisms. Moreover, several studies in murine and non-human primate models for SARS-CoV vaccines showed enhanced immunopathology, enhanced respiratory disease [41] or skewing immunological or inflammation-resolving response[37,42,43] on challenge with SARS CoV after immunization and thus the benefit of using SARS-CoV vaccine in humans was doubted[44] and a very interesting commentary that unfortunately has been unnoticed possibly because of multiple prior rejections at more visible journals has tested the outcomes of SARS CoV-2 infection in 33 African green monkeys which were vaccinated with mRNA SARS CoV-2 vaccines and ARDS has developed in one[45]. Accordingly, we disagree with Fu et al. [46] in their suggestion that an early, sub-optimal neutralizing antibody activity reasons for ADE responsible for the severe SARS CoV induced pulmonary disease and with Lee et al.[41] and in their suggestion, basing on interpretations of some murine models findings, that SARS CoV-2 vaccines that elicit high neutralizing antibody titres have a minimal risk of ADE which is supported by a preprinted study that used a SARS CoV-2 murine model[47] to be noted that neutralizing antibodies are described to induce ADE [42,48] and a SARS CoV-2 DNA study that has been performed in non-human primates and frequently cited to acquit COVID-19 from ADE potential has clearly stated that it was not designed to examine safety issues. Furthermore, it recommended future studies to specifically address the probability of enhanced respiratory disease due to ADE implying that their favorable impression should never be cited as potentially conclusive[49]. Importantly, another argument that is used as a principle to refute or underestimate COVID-19 ADE risk is that antibodies can have very different properties in animals compared to those in the human host, because of altered functional species-specific interactions between the antibody and immune cells[50] should be used

likewise in favor of the contradictory perspective as explained, further we suggest that results coming from non-corona viruses should not be considered of much significant value when trying to interpret the potential risk of ADE in COVID-19. Moreover, we suggest that while COVID-19 does not worsen after treatment with plasma from convalescent patients[50], it should also be considered irrelevant in a context that underestimate COVID-19 potential ADE risk for two reasons; the first is the timing as these antibodies are being administered to combat an undergoing infection and the other is that in fact these antibodies might actually have worsened COVID-19 if proper validation of cardiac events was conducted and thus an early ADE should not be excluded[51]. Alarming, unlike the one year spent to develop a vaccine for SARS CoV-2 (a single-stranded RNA virus), the journey to develop RSV (another enveloped non-segmented single stranded RNA virus) vaccine took more than 60 years and has not ended yet. More alarmingly, 80% of young infants previously vaccinated with inactivated RSV who have been subsequently infected with wild RSV experienced enhanced respiratory disease that required hospitalization and two died and [52] and an atypical measles illness accompanied by peripheral edema and pneumonia occurred in ten children who had received inactivated measles (a third enveloped non-segmented single stranded RNA virus) vaccine five to six years earlier and significant pleural effusions were noted in three of them[53]. Importantly, we wish to strongly recommend against any suggested administration of SARS CoV-2 vaccines to children especially the inactivated ones. Moreover, we confirm our recommendation using the lowest possible vaccination dose optimized to produce high-affinity anti-SARS CoV-2 IgG as this might be our route to decrease this and other potential likelihoods. Additionally, we reconfirm the need for developing suggested neutralizing nanobodies as well as new immunofocusing vaccines basing on the spike, N or other potential SARS CoV-2 immunological targets[37]. Finally, though reports of SARS CoV-2 infection early after vaccination have not reported ADE[54], yet the recent terrible surge of COVID-19 mortality in India should be further investigated whether SARS CoV-2 B.1.617 variants are the sole culprit and whether the enthusiastic Indian vaccination program might helped in the emergence of these potentially more lethal variants [55] and the timing of infection might also play a factor in development of ADE as well as some individualized immune-

genetic factors and thus, from our point of view, an advice for close and vigilant follow up should not be ignored and any report of such adverse effect should not be underestimated.

Who are the higher-risk groups, and could we lower their potential risk?

Notably, we would like to explore some groups of individuals who are potentially more vulnerable to autoimmune diseases, aiming to recommend a personalized risk benefit ratio to be considered before a decision to be immunized by adenovirus and RNA based SARS CoV-2 vaccine until encouraging post marketing safety data are revealed for all SARS CoV-2 types of vaccines. The first higher-risk group are female[56] and this is a non-modifiable risk factor and the second are smokers; cigarette smoke has been reported to lead to an enhanced risk of inflammatory and autoimmune diseases[57]. Smokers are more likely to develop critical COVID-19 requiring mechanical ventilation [58] that might lead to a higher mortality rate [59,60]. Interestingly, alarms about the danger of misreading non-significant or inconclusive frequentist results containing several possible biases of a contradictory hypotheses have been raised [61,62].

Two other important groups that might be closely monitored include obese and diabetic individuals; obesity was suggested to be a major environmental factor contributing to the onset and progression of autoimmune diseases[63] and a concomitant autoimmune disease was encountered as 1 in 4 of 179,248 people diagnosed with type 1 diabetes[64]. Notably, a meta-analysis has showed diabetes, but not obesity, to be linked to a higher COVID-19 mortality[65]. However, increasing risks of COVID-19 hospital death were noticed to be associated with increasing levels of obesity (BMI >40 fully adjusted HR 2.27, 95% CI 1.99-2.58)[66].

Interestingly, quitting smoking at diagnosis was recently shown to decrease the risk of death in cancer patients[67], and quitting smoking was suggested to alleviate its impact in patients with pneumonia and other COVID-19 associated infections[60,62,68], thus a beneficial advice to quit smoking together with another to lose overweight and to control the blood glucose levels might also help to lower the chances of SARS CoV-2 adenovirus and RNA-based vaccine potential autoimmunity in those individuals. Most importantly, we would like to stress the utmost importance to remind the participants to report all experienced adverse effects to a well-prepared post marketing surveillance system. Further,

the search to improve methods that help to develop nucleic acid-based vaccines with minimal autoimmune potential risk should continue and until more reassuring post marketing safety data are released, we recommend considering an individualized risk benefit ratio especially for those higher risk groups of patients.

Conclusion

In conclusion, we totally condemn, from a medical point of view, any national policy that necessitates these experimental vaccines and we also condemn the European Court of Human Rights shameful ruling that compulsory vaccination would not contravene human rights law [<https://www.dw.com/en/echr-rules-obligatory-vaccination-may-be-necessary/a-57128443>]. Moreover, though “experts” finally admit that their claimed vaccine induced herd immunity is very unlikely [69] or almost impossible [<https://www.nytimes.com/2021/05/03/health/covid-herd-immunity-vaccine.html>], they continue to make it almost compulsory and we condemn the trials made by some pharmaceutical companies to test those vaccines in children as well as their attempt to seek clearance of usage in children aged two years and above [https://www.nytimes.com/2021/05/04/health/pfizer-vaccine-children-approval.html?action=click&block=associated_collection_recirc&impression_id=d81bf912-ad21-11eb-879f-e72e2db5680e&index=2&pgtype=Article®ion=footer] as other than the discovered potential short term complications, long term ones are not excluded as well [36]. Notably, we are regretful that many “honorable” journals, including one affiliated to the CDC, have refused to peer review this manuscript though a draft was submitted to some several months ago and before the appearance of mortalities attributed to those vaccines. Ironically, nothing is comparable to this misfortunate dishonorable academic misconduct except the intended one year persistent denial, by dozens of similarly “reputable” journals to fairly review our immunomodulatory protocol that provides a safe, inexpensive cure to COVID-19 and even when it was accepted after peer review, some have intervened to remove it from publication[70]. We repeat urging the CDC to consider a change to its current recommendation to advise against use of nucleic acid based vaccination for COVID-19 patients complaining of autoimmune diseases and we suggest that FDA should investigate a potential extra risk that might be associated with BNT162b2

vaccine and calling for an independent re-evaluation of the post vaccination situation in Israel and we totally agreed with the EMA and FDA decisions to reevaluate the safety of ChAdOx1 nCoV-19 and Ad26.COV2-S vaccines, respectively. Furthermore, that risk benefit ratio from administering convalescent plasma to COVID-19 patients might be outbalanced due to potential early ADE. Moreover, a strict system for post vaccination surveillance must be secured to report any encountered serious adverse effect especially for those who would be reinfected with SARS CoV-2 despite vaccination. Additionally, the techniques used in development of all types of SARS CoV-2 vaccines, especially the newly emergency approved ones, should focus on innovative methods to decrease their potential autoimmunity and antibody dependent disease enhancement. Finally, in all cases we believe that a more careful consideration of these potential hazards must have been thoroughly discussed and/or refuted before a mass vaccination approval was granted as the public, which has been repeatedly denied a constitutional right to know, will not accept to prevent a minority of unaware recipients who experienced the presented adverse effects from their legal right to know first then decide, no matter if the adverse effects are rare as frequently claimed or not to the same extent that we will not withstand any political or economic gains that might have induced or would induce a man-made Hades currently or in the future and we wish to remind all stake-holders that no prior agreements will, ever, secure impunity.

Acknowledgments

This work is dedicated to Egypt; a country that I am proud to be one of its citizens, Africa; the continent that has suffered oppression for centuries and especially to my beloved mother to whom I owe my endurance and faith. The author would also like to sincerely thank Dr. James Lyons-Weiler (The Institute for Pure and Applied Knowledge; US) who after reading a preprint has generously emailed three valuable immunology related references that have enriched this and other manuscripts and I am also very grateful to Dr. Viera Malachovska, Ing, PhD a Slovakian scientist who has generously emailed precious links that discusses the safety concerns related to the BNT162b2 vaccine in Israel. I am also very much indebted to the precious feedback that has reached me from several

individuals from many countries who have generously shared their reasonable doubt, fear and hopes after reading a preprint of this manuscript.

Funding

None

Conflict of interest

The author declares that he has no conflict of interest.

References

1. Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. *Vaccine*. 2020 2020/09/11/;38(40):6194-6198.
2. Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. *Drug Safety*. 2020 2020/09/30.
3. Shakir S, Lane S, Davies M. How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine. *Drug Safety*. 2021 2021/01/01;44(1):1-5.
4. Heidi Ledford. US authorization of first COVID vaccine marks new phase in safety monitoring. *Nature*,. 2020, December 12;588:377-378.
5. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. *Journal of Translational Autoimmunity*. 2020 2020/01/01/;3:100051.
6. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity*. 2010;33(4):492-503.
7. Reuters (Ludwig Burger). AstraZeneca pauses coronavirus vaccine trial as participant illness investigated 2020, September 09. Available from: <https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-pauses-coronavirus-vaccine-trial-rollout-doubts-dent-shares-idUSKBN26017L>
8. Statnews (MATTHEW HERPER). Covid-19 vaccine trials from AstraZeneca, Johnson & Johnson to restart 2020, October 23. Available from: <https://www.statnews.com/2020/10/23/covid-19-vaccine-trials-from-astrazeneca-johnson-johnson-to-restart/>
9. Ledford SMH. COVID-vaccine results are on the way — and scientists’ concerns are growing. *Nature*. 2020, September 25. Available from: <https://www.nature.com/articles/d41586-020-02706-6>
10. Reuters. J&J pauses COVID-19 vaccine trials due to unexplained illness in participant 2020, October 13. Available from: <https://www.reuters.com/article/uk-health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-unexplained-illness-in-participant-idUKKBN26Y02L>
11. The New York Times (Rebecca Robbins and Benjamin Mueller). After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine 2020, November 25. Available from: <https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html>

- 473 12. Wagner TE, Becraft JR, Bodner K, et al. Small-molecule-based regulation of RNA-
474 delivered circuits in mammalian cells. *Nature Chemical Biology*. 2018
475 2018/11/01;14(11):1043-1050.
- 476 13. Wen Y-M, Mu L, Shi Y. Immunoregulatory functions of immune complexes in vaccine
477 and therapy. *EMBO Mol Med*. 2016;8(10):1120-1133.
- 478 14. Zhang C, Maruggi G, Shan H, et al. Advances in mRNA Vaccines for Infectious Diseases
479 [Review]. *Frontiers in Immunology*. 2019 2019-March-27;10(594).
- 480 15. Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines — a new era in vaccinology. *Nature*
481 *Reviews Drug Discovery*. 2018 2018/04/01;17(4):261-279.
- 482 16. Andries O, Kitada T, Bodner K, et al. Synthetic biology devices and circuits for RNA-based
483 'smart vaccines': a propositional review. *Expert Review of Vaccines*. 2015
484 2015/02/01;14(2):313-331.
- 485 17. Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-SARS-CoV-2
486 Vaccine Development. *Med Sci Monit*. 2020;26:e924700-e924700.
- 487 18. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious
488 diseases. *Gene Therapy*. 2020 2020/10/22.
- 489 19. NTV. Zusammenhang unwahrscheinlich: Institut prüft zehn Todesfälle nach Impfung
490 [German]. 2021, January 14.
- 491 20. Guo L, Rondina MT. The Era of Thromboinflammation: Platelets Are Dynamic Sensors
492 and Effector Cells During Infectious Diseases. *Front Immunol*. 2019;10:2204.
- 493 21. Hoffman M, Monroe DM, Roubey RA. Links between the immune and coagulation
494 systems: how do "antiphospholipid antibodies" cause thrombosis? *Immunol Res*.
495 2000;22(2-3):191-7.
- 496 22. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity.
497 *Nature Reviews Immunology*. 2013 2013/01/01;13(1):34-45.
- 498 23. Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: A
499 narrative review with emphasis on primary systemic vasculitides. *Vascular Medicine*.
500 2015 2015/08/01;20(4):369-376.
- 501 24. Aggarwal S, Sharma N. Cerebral venous sinus thrombosis with autoimmune thyroiditis.
502 *Indian J Endocrinol Metab*. 2013;17(Suppl 1):S176-S177.
- 503 25. Carhuapoma Juan R, Mitsias P, Levine Steven R. Cerebral Venous Thrombosis and
504 Anticardiolipin Antibodies. *Stroke*. 1997 1997/12/01;28(12):2363-2369.
- 505 26. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after
506 ChAdOx1 nCov-19 Vaccination. *New England Journal of Medicine*. 2021.
- 507 27. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With
508 Thrombocytopenia After Ad26.COVS.2.S Vaccination, March 2 to April 21, 2021. *JAMA*.
509 2021.
- 510 28. Maxime Taquet MH, John R Geddes, Sierra Luciano, Paul J Harrison. Cerebral venous
511 thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a
512 comparison with 489,871 people receiving a COVID-19 mRNA vaccine. *OSFPREPRINTS*
513 (Preprint). 2021.
- 514 29. Bracamonte-Baran W, Čiháková D. Cardiac Autoimmunity: Myocarditis. *Adv Exp Med*
515 *Biol*. 2017;1003:187-221.
- 516 30. Khalil A, Naneishvili T, Prasad N, et al. SARS-CoV-2 myocarditis: what physicians need to
517 know. *BMJ Evidence-Based Medicine*. 2021:bmjebm-2020-111527.
- 518 31. Esfandiarei M, McManus BM. Molecular Biology and Pathogenesis of Viral Myocarditis.
519 *Annual Review of Pathology: Mechanisms of Disease*. 2008 2008/02/01;3(1):127-155.

520 32. Savvatis K, Müller I, Fröhlich M, et al. Interleukin-6 receptor inhibition modulates the
521 immune reaction and restores titin phosphorylation in experimental myocarditis. *Basic*
522 *Research in Cardiology*. 2014 2014/10/25;109(6):449.

523 33. Kelleni MT. Non-steroidal Anti-inflammatory Drugs/nitazoxanide/azithromycin Potential
524 Beneficial COVID-19 Effects: Preventing the Cytokine Storm via Mitigation of the
525 Interleukin-6 Amplifier and Monocytic Immunological Dysrhythmia. *OSFPREPRINTS*
526 (Preprint).

527 34. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to
528 vaccination. *Human vaccines & immunotherapeutics*. 2016;12(9):2391-2402.

529 35. Karaderi T, Bareke H, Kunter I, et al. Host Genetics at the Intersection of Autoimmunity
530 and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity [Perspective].
531 *Front Immunol*. 2020 2020-December-22;11(3314).

532 36. Kira Smith. BNT162b2 Vaccine: Possible Codons Misreading, Errors in Protein Synthesis
533 and Alternative Splicing's Anomalies. *Journal of Antivirals & Antiretrovirals*. 2021;13(2).

534 37. Karthik K, Senthilkumar TMA, Udhayavel S, et al. Role of antibody-dependent
535 enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the
536 development of vaccines and immunotherapies to counter COVID-19. *Human Vaccines*
537 *& Immunotherapeutics*. 2020 2020/12/01;16(12):3055-3060.

538 38. Yip MS, Leung NHL, Cheung CY, et al. Antibody-dependent infection of human
539 macrophages by severe acute respiratory syndrome coronavirus. *Virol J*. 2014;11:82-82.

540 39. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect*.
541 2020;22(2):72-73.

542 40. Adrielle dos Santos L, Filho PGdG, Silva AMF, et al. Recurrent COVID-19 including
543 evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers.
544 *Journal of Infection*.

545 41. Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2
546 vaccines and therapies. *Nature Microbiology*. 2020 2020/10/01;5(10):1185-1191.

547 42. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing
548 macrophage responses during acute SARS-CoV infection. *JCI Insight*. 2019;4(4):e123158.

549 43. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus
550 vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PLoS*
551 *One*. 2012;7(4):e35421.

552 44. Yip MS, Cheung CY, Li PH, et al. Investigation of Antibody-Dependent Enhancement
553 (ADE) of SARS coronavirus infection and its role in pathogenesis of SARS. *BMC*
554 *Proceedings*. 2011 2011/01/10;5(1):P80.

555 45. Farshi E. Cytokine Storm Response to COVID-19 Vaccinations. *Journal of Cytokine*
556 *Biology*. 2020;5: 1000125

557 46. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses:
558 From Mechanisms to Potential Therapeutic Tools. *Virologica Sinica*. 2020
559 2020/06/01;35(3):266-271.

560 47. Quinlan BD, Mou H, Zhang L, et al. The SARS-CoV-2 receptor-binding domain elicits a
561 potent neutralizing response without antibody-dependent enhancement. *bioRxiv*.
562 2020:2020.04.10.036418.

563 48. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19.
564 *Nat Rev Immunol*. 2020;20(6):339-341.

565 49. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus
566 macaques. *Science*. 2020;369(6505):806-811.

567 50. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent
568 enhancement of SARS-CoV-2. *Nature*. 2020 2020/08/01;584(7821):353-363.

569 51. Pathak EB. Convalescent plasma is ineffective for covid-19. *BMJ*. 2020;371:m4072.

570 52. Mejias A, Rodríguez-Fernández R, Oliva S, et al. The journey to a respiratory syncytial
571 virus vaccine. *Annals of Allergy, Asthma & Immunology*. 2020;125(1):36-46.

572 53. Fulginiti VA, Eller JJ, Downie AW, et al. Altered Reactivity to Measles Virus: Atypical
573 Measles in Children Previously Immunized With Inactivated Measles Virus Vaccines.
574 *JAMA*. 1967;202(12):1075-1080.

575 54. Amit S BS, Biber A, Grinberg A, Leshem E, Regev-Yochay G. . Post-vaccination COVID-19
576 among healthcare workers, Israel. *Emerg Infect Dis*. 2021.

577 55. Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern? *The*
578 *Lancet Respiratory Medicine*. 2021;9(4):333-335.

579 56. Angum F, Khan T, Kaler J, et al. The Prevalence of Autoimmune Disorders in Women: A
580 Narrative Review. *Cureus*. 2020;12(5):e8094-e8094.

581 57. Hussain MS, Tripathi V. Smoking under hypoxic conditions: a potent environmental risk
582 factor for inflammatory and autoimmune diseases. *Mil Med Res*. 2018 Mar 30;5(1):11.

583 58. Adrish M, Chilimuri S, Mantri N, et al. Association of smoking status with outcomes in
584 hospitalised patients with COVID-19. *BMJ Open Respir Res*. 2020 Oct;7(1).

585 59. Jimenez-Ruiz CA, Lopez-Padilla D, Alonso-Arroyo A, et al. COVID-19 and Smoking: A
586 Systematic Review and Meta-Analysis of the Evidence. *Arch Bronconeumol*. 2020 Jul 25.

587 60. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19
588 particularly among younger adults: A systematic review and meta-analysis. *medRxiv*.
589 2020 Sep 23.

590 61. Usman MS, Siddiqi TJ, Khan MS, et al. Is there a smoker's paradox in COVID-19? *BMJ*
591 *Evidence-Based Medicine*. 2020:bmjebm-2020-111492.

592 62. Carmona-Bayonas A, Jimenez-Fonseca P, Sánchez Arraez Á, et al. Does active smoking
593 worsen Covid-19? *Eur J Intern Med*. 2020;77:129-131.

594 63. Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive
595 bystander. *Autoimmun Rev*. 2014 Sep;13(9):981-1000.

596 64. Rogers MAM, Wei MY, Kim C, et al. Sex Differences in Autoimmune Multimorbidity in
597 Type 1 Diabetes Mellitus and the Risk of Cardiovascular and Renal Disease: A
598 Longitudinal Study in the United States, 2001-2017. *J Womens Health (Larchmt)*. 2020
599 Apr;29(4):511-519.

600 65. Figliozi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A
601 systematic review and meta-analysis [<https://doi.org/10.1111/eci.13362>]. *European*
602 *Journal of Clinical Investigation*. 2020 2020/10/01;50(10):e13362.

603 66. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with
604 COVID-19-related hospital death in the linked electronic health records of 17 million
605 adult NHS patients. *medRxiv*. 2020:2020.05.06.20092999.

606 67. Yang S, Liu T, Liang G. The benefits of smoking cessation on survival in cancer patients by
607 integrative analysis of multi-omics data. *Mol Oncol*. 2020 Jun 24.

608 68. CDC. Coronavirus Disease 2019 (COVID-19): People with Certain Medical Conditions
609 2020, November 02. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking)
610 [ncov/need-extra-precautions/people-with-medical-conditions.html#smoking](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking)

611 69. Grant A, Hunter PR. Immunisation, asymptomatic infection, herd immunity and the new
612 variants of COVID 19. *medRxiv*. 2021:2021.01.16.21249946.

613 70. Kelleni M. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in
614 Adults, Children and Pregnant COVID-19 Patients: An Egyptian Prospective
615 Observational Study. OSFPREPRINTS (Preprint). 2021.